Web Analytics

3 Latest Announced Rounds

  • $30,000,000
    Series B

    5 Investors

    Food and Beverage Services
    Nov 19th, 2024
  • $316,823
    Unknown

    1 Investors

    IT Services and IT Consulting
    Nov 19th, 2024
  • $7,200,000
    Seed

    1 Investors

    Software Development
    Nov 19th, 2024
$1,856.00M Raised in 85 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Mestastop® Solutions

start up
United States - Marlton, New Jersey
  • 20/10/2023
  • Pre Series A
  • $500,000

Cancer can be broken down into four parts; mainly initiation, progression, immunosuppression, and finally metastasis, leading to death. Initiation and progression happen due to genetic reasons along with the interplay of the tumor microenvironment, whereas immunosuppression is the inefficiency of the body’s immune system to recognize and destroy cancer cells. Metastasis is the movement of tumor cells through the blood and the formation of multiple tumors into different secondary sites of the body. Metastasis is responsible for almost 90% of cancer deaths.

Unfortunately, though cancer treatment has advanced with targeted therapy and immunotherapy, there is still a huge gap as none of them addresses metastasis. One of the main reasons for these are the challenges faced in advancing a molecule targeting metastasis; from suitable In vitro models to the perfect animal model that will closely resemble the biology without alleviating cost and timelines.

Mestastop aims to provide a solution for such challenges with their unique proprietary platforms, METAssay, METSCAN, and METVivo.


Related People

Arnab Roy ChowdhuryFounder

Arnab Roy Chowdhury India - Bengaluru, Karnataka

As the founder of Mestastop Solutions, Arnab is passionate about solving the unmet medical need of cancer metastasis, which accounts for 90% of cancer deaths. With 23 years of experience in applied therapeutics, he have led eight discovery programs, four in cancer biology, and delivered a pre-IND candidate for triple-negative breast cancer.

Arnab mission is to develop novel platforms and predictive diagnostics that can identify and target the rate-limiting steps of metastasis. Mestastop have built three platforms, METAssay®, METVIVO®, and METVivo®, that fill the gaps in drug discovery and validation. They have also conducted prospective and retrospective clinical studies to demonstrate the translational potential of the approach. Arnab & Mestastop is driven by the desire to make a difference in the lives of cancer patients and their families.